A Reasonable First Move for Dyspepsia Nobody Has Looked Inside Yet
A single patient with three weeks of new dyspepsia and no worrisome features. The disagreement is between the strategy that answers the question and the strategy that relieves the symptom fastest — and whether both can happen at once.
J.K., a 34-year-old warehouse shift supervisor, came into urgent care on his lunch break with three weeks of upper-abdominal discomfort and early fullness after meals — nothing that's stopped him from working a physical job, but enough that he's started skipping lunch to avoid the discomfort altogether. He has no weight loss, no bleeding, no dysphagia, no family history of gastric cancer, and is under 40, the age threshold below which most dyspepsia guidelines don't recommend upfront endoscopy absent alarm features.
Two reasonable first moves exist for exactly this presentation, and the choice between them isn't really about which is more effective — both are guideline-endorsed and both work reasonably well in trials — it's about what each one is actually testing for. Empiric PPI therapy treats acid-related dyspepsia directly and works whether or not H. pylori is present, but if his symptoms are H. pylori-driven, a PPI trial suppresses the symptom without addressing the infection, meaning a taper or discontinuation risks the same symptoms resurfacing. H. pylori test-and-treat, by contrast, uses a noninvasive stool antigen or urea breath test to check for the specific driver before committing to therapy, and treats the infection directly if positive — a genuinely curative move where empiric PPI therapy is only ever symptomatic.
Chey and colleagues' ACG guideline on H. pylori, and the AGA's dyspepsia guidance alongside it, both endorse test-and-treat as the preferred initial strategy where prevalence is meaningfully high, precisely because it avoids the scenario where a patient spends months on acid suppression for an infection that was identifiable and treatable from the start; the argument for empiric PPI therapy is faster symptom relief while results are pending, not a claim that it is the more complete answer. That preference is conditional on prevalence, and J.K.'s community is where the condition is met — regional surveillance puts local prevalence in the band where the number needed to test to find one true infection stays favorable. In a low-prevalence population the same guideline logic would tip back toward empiric therapy alone, so the strategy is being chosen on his epidemiology, not on its general reputation.
Speed of relief against speed of an actual answer
He's already skipping lunch to manage this, working a physical job where that's not sustainable. I'd start empiric PPI therapy today — it treats acid-related dyspepsia whether or not H. pylori turns out to be involved, and he gets relief now instead of waiting on a test result.
I understand wanting to give him relief immediately, and I'm not dismissing how much three weeks of this has already cost him at work.
But if H. pylori is actually driving this — and local prevalence here is high enough to make that a real possibility, not a remote one — empiric PPI therapy only suppresses the symptom. The infection stays untreated, and the moment he tapers off or the drug's effect wanes, the same discomfort is likely to come right back, just later and after he's already spent weeks assuming the PPI worked. Test-and-treat gets him a curative answer, not just a quiet one.
I'll grant the curative point — if he's positive, you're right that a PPI only quiets it. But I want to name what your own plan depends on, because it isn't a free option. Stool antigen and urea breath testing both go falsely negative on a proton pump inhibitor; that's why you reached for famotidine and not omeprazole as the bridge. Which means "start empiric PPI today and test later if he doesn't improve" was never actually available to us as a fallback — starting the PPI is what takes the test away for the next two weeks. So this isn't relief now versus answers later. It's one or the other, and I'd rather we said that out loud than discovered it when his result came back negative on a drug he'd already started.
The wait for a stool antigen result is typically only a few days, not weeks — I'd send it today and start him on an over-the-counter H2-receptor antagonist in the meantime for symptom bridging, so he isn't simply told to wait it out at work with nothing.
Urea breath test sent today, with famotidine offered as interim symptom relief while results are pending, and eradication therapy named explicitly as the next step if the test returns positive rather than left as an unplanned contingency.
Both agreed on the final plan; the Primary Care Physician's instinct toward faster relief shaped the bridging therapy added to the plan, even though the definitive strategy — test first — was adopted as written.